News & Updates

Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.

Heart surgery during the COVID-19 pandemic took a turn for the worse, with higher cost and poorer survival regardless of people’s socioeconomic status, according to US data.

In a meta-analysis of national cohort studies on COVID-19 vaccination across the UK (England, Northern Ireland, Scotland, and Wales), undervaccination was associated with a higher risk of severe COVID-19 outcomes (ie, COVID-19 hospitalization or death) relative to full vaccination.